Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus con-current chemoradiotherapy in patients with locally advanced squamous cell car-cinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.

Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators.

Lancet Oncol. 2024 Mar 29:S1470-2045(24)00100-1. doi: 10.1016/S1470-2045(24)00100-1. Online ahead of print. PMID: 38561010.

https://pubmed.ncbi.nlm.nih.gov/38561010/